Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146.
| Title: | Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. |
|---|---|
| Authors: | Lee, Chung-Han1 (AUTHOR), Yogesh Shah, Amishi2 (AUTHOR), Rao, Arpit3 (AUTHOR), Taylor, Matthew H.4 (AUTHOR), Di Simone, Christopher5 (AUTHOR), Hsieh, James J.6 (AUTHOR), Pinto, Alvaro7 (AUTHOR), Gironés Sarrió, Regina8 (AUTHOR), Lee Cohn, Allen9 (AUTHOR), Asim Bilen, Mehmet10 (AUTHOR), Gunnestad Ribe, Sara11 (AUTHOR), Krohn Tennøe, Øyvind12 (AUTHOR), Richards, Donald13 (AUTHOR), Sweis, Randy F.14 (AUTHOR), Courtright, Jay15 (AUTHOR), Heinrich, Daniel16 (AUTHOR), Perini, Rodolfo17 (AUTHOR), Kubiak, Peter1,18 (AUTHOR), Bock, Daena19 (AUTHOR), Okpara, Chinyere E.20 (AUTHOR) |
| Source: | European Urology. Nov2024, Vol. 86 Issue 5, p470-473. 4p. |
| Subject Terms: | *IMMUNE checkpoint inhibitors, *RENAL cell carcinoma, *PEMBROLIZUMAB, *METASTASIS, *THERAPEUTICS |
| Database: | Academic Search Complete |
| ISSN: | 03022838 |
|---|---|
| DOI: | 10.1016/j.eururo.2024.05.003 |
| Published in: | European Urology |
| Language: | English |